At a press conference at ECC 2015, Dr Lambertini presents the results of a meta-analysis suggesting that young women undergoing chemotherapy for breast cancer that may be more likely to remain fertile if they receive temporary treatment with a hormone-releasing hormone agonist (LHRHa).

A total of 12 randomized trials were included in the meta-analysis, accounting for 1,231 women with breast cancer.

The use of a LHRHa was found to significantly reduce the risk of chemotherapy-induced premature ovarian failure and seemed to be associated with a higher pregnancy rate in young breast cancer patients.

Watch the video interview and read the news story for more.